Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840970 | 0.89 | DRD2 (0.37) | DRD2DRD1NOS3NOS1NOS2 | |
| SCHEMBL10238797 | 0.79 | DRD2 (0.40) | DRD2DRD1NOS3NOS1NOS2 | |
| SCHEMBL25917715 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL21065642 | 0.78 | — | — | |
| SCHEMBL24327696 | 0.78 | HTT (0.35) | — | |
| SCHEMBL20840973 | 0.77 | HRH4 (0.31) | — | |
| SCHEMBL24326944 | 0.75 | PDPK1 (0.40) | DRD2DRD1PDK2PDK4 | |
| SCHEMBL24336496 | 0.75 | DRD2 (0.37) | DRD2DRD1PDK2PDK4 | |
| SCHEMBL16692275 | 0.73 | DRD2 (0.38) | DRD2DRD1NOS3NOS1NOS2 | |
| SCHEMBL14853329 | 0.71 | MAPT (0.41) | DRD2DRD1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2019118884-A1 | ANTIBODY CONSTRUCT-DRUG CONJUGATE FOR THE TREATMENT OF HEPATITIS | SILVERBACK THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |